Nexell hands back Isolex rights to Baxter
This article was originally published in Clinica
Executive Summary
Nexell Therapeutics is to transfer exclusive worldwide sales, marketing and distribution rights for its cell processing products, including the Isolex 300i magnetic cell selection system, to Baxter Healthcare. Nexell will also cut around two-thirds of its staff in restructuring measures to streamline operations and reduce expenditure.